Pilot safety trial of deferiprone in 10 subjects with superficial siderosis

Michael Levy, Rafael H Llinas

Research output: Contribution to journalArticle

Abstract

Background and Purpose-: Superficial siderosis is a neurodegenerative disease caused by toxic accumulation of hemosiderin on the surface of the brain and spinal cord for which there is no known effective treatment. Methods-: Oral deferiprone, a lipid-soluble iron chelator with ability to cross the blood-brain barrier, at a dose of 30 mg/kg per day was tested for safety in an open pilot study in 10 subjects with superficial siderosis. Results-: Over a 90-day period, deferiprone had no significant adverse effects on hematologic, liver, or neurological function. Ad hoc MRI assessments of the brain indicated a reduction in hemosiderin deposition in some subjects. Conclusions-: Deferiprone proved safe in this small population of superficial siderosis subjects. There was MRI evidence of reduced hemosiderin deposition with deferiprone. Prospectively designed efficacy studies are necessary to determine the clinical efficacy of deferiprone in superficial siderosis.

Original languageEnglish (US)
Pages (from-to)120-124
Number of pages5
JournalStroke
Volume43
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Siderosis
Hemosiderin
Safety
Poisons
Brain
Chelating Agents
Blood-Brain Barrier
Neurodegenerative Diseases
Spinal Cord
Iron
deferiprone
Lipids
Liver
Population

Keywords

  • deferiprone
  • hemosiderosis
  • superficial siderosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Pilot safety trial of deferiprone in 10 subjects with superficial siderosis. / Levy, Michael; Llinas, Rafael H.

In: Stroke, Vol. 43, No. 1, 01.2012, p. 120-124.

Research output: Contribution to journalArticle

@article{bfe87be01e7543a8ac4da07de77b9f89,
title = "Pilot safety trial of deferiprone in 10 subjects with superficial siderosis",
abstract = "Background and Purpose-: Superficial siderosis is a neurodegenerative disease caused by toxic accumulation of hemosiderin on the surface of the brain and spinal cord for which there is no known effective treatment. Methods-: Oral deferiprone, a lipid-soluble iron chelator with ability to cross the blood-brain barrier, at a dose of 30 mg/kg per day was tested for safety in an open pilot study in 10 subjects with superficial siderosis. Results-: Over a 90-day period, deferiprone had no significant adverse effects on hematologic, liver, or neurological function. Ad hoc MRI assessments of the brain indicated a reduction in hemosiderin deposition in some subjects. Conclusions-: Deferiprone proved safe in this small population of superficial siderosis subjects. There was MRI evidence of reduced hemosiderin deposition with deferiprone. Prospectively designed efficacy studies are necessary to determine the clinical efficacy of deferiprone in superficial siderosis.",
keywords = "deferiprone, hemosiderosis, superficial siderosis",
author = "Michael Levy and Llinas, {Rafael H}",
year = "2012",
month = "1",
doi = "10.1161/STROKEAHA.111.628032",
language = "English (US)",
volume = "43",
pages = "120--124",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Pilot safety trial of deferiprone in 10 subjects with superficial siderosis

AU - Levy, Michael

AU - Llinas, Rafael H

PY - 2012/1

Y1 - 2012/1

N2 - Background and Purpose-: Superficial siderosis is a neurodegenerative disease caused by toxic accumulation of hemosiderin on the surface of the brain and spinal cord for which there is no known effective treatment. Methods-: Oral deferiprone, a lipid-soluble iron chelator with ability to cross the blood-brain barrier, at a dose of 30 mg/kg per day was tested for safety in an open pilot study in 10 subjects with superficial siderosis. Results-: Over a 90-day period, deferiprone had no significant adverse effects on hematologic, liver, or neurological function. Ad hoc MRI assessments of the brain indicated a reduction in hemosiderin deposition in some subjects. Conclusions-: Deferiprone proved safe in this small population of superficial siderosis subjects. There was MRI evidence of reduced hemosiderin deposition with deferiprone. Prospectively designed efficacy studies are necessary to determine the clinical efficacy of deferiprone in superficial siderosis.

AB - Background and Purpose-: Superficial siderosis is a neurodegenerative disease caused by toxic accumulation of hemosiderin on the surface of the brain and spinal cord for which there is no known effective treatment. Methods-: Oral deferiprone, a lipid-soluble iron chelator with ability to cross the blood-brain barrier, at a dose of 30 mg/kg per day was tested for safety in an open pilot study in 10 subjects with superficial siderosis. Results-: Over a 90-day period, deferiprone had no significant adverse effects on hematologic, liver, or neurological function. Ad hoc MRI assessments of the brain indicated a reduction in hemosiderin deposition in some subjects. Conclusions-: Deferiprone proved safe in this small population of superficial siderosis subjects. There was MRI evidence of reduced hemosiderin deposition with deferiprone. Prospectively designed efficacy studies are necessary to determine the clinical efficacy of deferiprone in superficial siderosis.

KW - deferiprone

KW - hemosiderosis

KW - superficial siderosis

UR - http://www.scopus.com/inward/record.url?scp=84855347130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855347130&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.111.628032

DO - 10.1161/STROKEAHA.111.628032

M3 - Article

C2 - 22034002

AN - SCOPUS:84855347130

VL - 43

SP - 120

EP - 124

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 1

ER -